Micro-immunotherapy in rheumatology

Bone and joint disorders affect millions of people worldwide and occur increasingly more frequently as the population ages. These conditions include osteoporosis, rheumatoid arthritis, fibromyalgia, Bekhterev’s syndrome, Sjögren’s syndrome, psoriasis arthritis, as well as systemic lupus erythematosus.

These diseases are often multifactorial; not only degenerative processes, but also infectious and autoimmune factors such as trauma, play important roles as causal and risk factors. Most of these conditions follow a chronic course and cause different symptoms, ranging from joint pain, reduced mobility and bone weakness, through to invalidity.

Inflammation and immunological imbalances are closely related to the onset and progression of bone and joint disorders. In this context, micro-immunotherapy aims to limit the inflammation processes responsible for joint damage, to decelerate bone degeneration, as well as to counteract the tendency for it to become chronic.

1. Hardy, R., Cooper, M.S. Bone loss with inflammation. Journal of Endocrinology 2009. 201, 309–320.
2. Bultink IE, Vis M, van der Horst-Bruinsma IE, Lems WF. Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep. 2012;14(3):224-230.
3. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis. 2013;5(2):77-94.